NDA 020232 · Actavis Labs Ut INC
Fioricet W/ Codeine
Acetaminophen, Butalbital, Caffeine, Codeine Phosphate · Oral · Barbiturate; Central Nervous System Stimulant; Methylxanthine
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Jul 30, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,695
325 Phase 3, 144 recruiting
FAERS reports
38
35 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE PHOSPHATE CAPSULES Addiction, Abuse, and Misuse Because the use of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Butalbital, Acetaminophen,...
What it is approved for
From the label in effect Jan 9, 2026.
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy, [see Warnings and Precautions ( 5.1 )], reserve opioid analgesics, including Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsule is a combination product of butalbital, a barbiturate; acetaminophen; caffeine, a methylxanthine; and codeine phosphate, an opioid agonist; and is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesic and alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy, reserve opioid analgesics, including Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )
Mechanism: Butalbital, a barbiturate, is a GABA A receptor agonist and may inhibit excitatory AMPA receptors. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. Caffeine is a methylxanthine and CNS stimulant. The exact mechanism with respect to the indication is not clear; however, the effects of caffeine may be due to antagonism of adenosine receptors. Codeine is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 1992 Original approval · Type 5 - New Formulation or New Manufacturer REMS
1 products under this application
- FIORICET W/ CODEINE · ACETAMINOPHEN 325MG; BUTALBITAL 50MG; CAFFEINE 40MG; CODEINE PHOSPHATE 30MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
- A Study of a Candidate COVID-19 Vaccine (COV003)Pivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04536051 · 10,300 participants (planned) · Start Jun 2, 2020 · Primary completion Sep 2021
Drug: ChAdOx1 nCoV-19 single dose + paracetamol; MenACWY single dose + paracetamol and 2 more · For: Coronavirus
Sites: Salvador, Brazil; Natal, Brazil; Porto Alegre, Brazil · 6 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac SurgeryPivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06653465 · 1,930 participants (planned) · Start Jun 2025 · Primary completion Jun 2027
Drug: Acetaminophen; Saline · For: Delirium in Old Age
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183688 · 1,889 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: Low dose ASA; High dose ASA and 4 more · For: Migraine Disorders
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dependence27
- overdose15
- completed suicide5
- death3
- drug ineffective3
- cardio-respiratory arrest2
- maternal exposure during pregnancy2
- withdrawal syndrome2
- aggression1
- anxiety1
- blood testosterone decreased1
- constipation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 27 |
| 2024 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
Tan E, Braithwaite I, McKinlay CJD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Acetaminophen changes Mu rhythm power related to pain empathy.
Jelsone-Swain L, McCommon SA, Turk B, et al. · Neuropsychologia 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, et al. · Headache 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Bannuru RR, Schmid CH, Kent DM, et al. · Ann Intern Med 2015 · Research Support, N.I.H., Extramural, Systematic Review
Sponsor: Actavis Labs Ut INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.